Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

47.32 -1.43 (-2.93%)
Streaming Delayed Price Updated: 10:23 AM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 385,086
Open 47.83
Bid (Size) 47.32 (19)
Ask (Size) 47.34 (3)
Prev. Close 48.75
Today's Range 47.23 - 47.87
52wk Range 36.91 - 58.10
Shares Outstanding 1,250,690,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Earnings Outlook For Sanofi
 
Via Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga

Performance

YTD
-3.43%
-3.43%
1 Month
-3.43%
-3.43%
3 Month
+10.20%
+10.20%
6 Month
-3.13%
-3.13%
1 Year
-8.35%
-8.35%

More News

Read More
Sanofi Layoffs 2023: What to Know About the Latest SNY Job Cuts
Via InvestorPlace
Sanofi Might Pull Down Shutters For Two Vaccine Plants In India
Via Benzinga
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
Via Benzinga
Hopeful Golden Cross Forms On Sanofi's Chart
Via Benzinga
What Does Sanofi's Debt Look Like?
Via Benzinga
Sanofi Forecasts Foreign Exchange, Record Flu Vaccine Sales To Boost Q4 Earnings
Via Benzinga
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Could This Vaccine Become Sanofi's Latest Blockbuster?
Via The Motley Fool
7 Blue-Chip Stocks to Buy as a New Bull Market Emerges
Via InvestorPlace
Mergers and Acquisitions in 2023 Off To A Strong Start
Via MarketBeat
Exposures Product Safety
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
Via The Motley Fool
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
Via Investor's Business Daily
The Viral “Tripledemic” Opportunity
Via Talk Markets
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Via Benzinga
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics
Via Benzinga
What This Drug News Could Mean for Sanofi Shareholders
Via The Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
Via InvestorPlace
FDA Permits Pharmacies To Distribute Abortion Pills, Tesla's Aggressive Discounting May Have Hit Gross Margins, Goldman Sachs Bullish On M&A Activity In Late 2023: Top Stories Today
Via Benzinga
Could This Drug News Give a Lift to Eli Lilly Stock?
Via The Motley Fool
3 Medical Dividend Stocks That Hit the Sweet Spot
Via The Motley Fool
After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs
Via Benzinga
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
From Innate Pharma SA
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.